KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Cash (2016 - 2025)

Inovio Pharmaceuticals' Change in Cash history spans 16 years, with the latest figure at $12.2 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 196.15% year-over-year to $12.2 million; the TTM value through Sep 2025 reached $14.9 million, up 416.15%, while the annual FY2024 figure was $51.5 million, 260.85% up from the prior year.
  • Change in Cash for Q3 2025 was $12.2 million at Inovio Pharmaceuticals, up from -$15.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $44.1 million in Q4 2024 and bottomed at -$167.1 million in Q1 2021.
  • The 5-year median for Change in Cash is -$12.1 million (2022), against an average of -$11.3 million.
  • The largest annual shift saw Change in Cash surged 1081.94% in 2024 before it plummeted 589.47% in 2025.
  • A 5-year view of Change in Cash shows it stood at $3.2 million in 2021, then skyrocketed by 660.08% to $24.3 million in 2022, then tumbled by 118.46% to -$4.5 million in 2023, then soared by 1081.94% to $44.1 million in 2024, then tumbled by 72.32% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Change in Cash are $12.2 million (Q3 2025), -$15.6 million (Q2 2025), and -$25.9 million (Q1 2025).